These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

222 related items for PubMed ID: 32729092

  • 1. Real-world experience of lenvatinib in patients with advanced anaplastic thyroid cancer.
    Kim M, Ahn J, Song DE, Yoon JH, Kang HC, Lim DJ, Kim WG, Kim TY, Kim WB, Shong YK, Jeon MJ, Kim BH.
    Endocrine; 2021 Feb; 71(2):427-433. PubMed ID: 32729092
    [Abstract] [Full Text] [Related]

  • 2. Salvage Lenvatinib Therapy in Metastatic Anaplastic Thyroid Cancer.
    Iñiguez-Ariza NM, Ryder MM, Hilger CR, Bible KC.
    Thyroid; 2017 Jul; 27(7):923-927. PubMed ID: 28471306
    [Abstract] [Full Text] [Related]

  • 3. A Phase II study of the safety and efficacy of lenvatinib in patients with advanced thyroid cancer.
    Takahashi S, Kiyota N, Yamazaki T, Chayahara N, Nakano K, Inagaki L, Toda K, Enokida T, Minami H, Imamura Y, Fukuda N, Sasaki T, Suzuki T, Ikezawa H, Dutcus CE, Tahara M.
    Future Oncol; 2019 Mar; 15(7):717-726. PubMed ID: 30638399
    [Abstract] [Full Text] [Related]

  • 4. Real-World Experience with Targeted Therapy for the Treatment of Anaplastic Thyroid Carcinoma.
    Iyer PC, Dadu R, Ferrarotto R, Busaidy NL, Habra MA, Zafereo M, Gross N, Hess KR, Gule-Monroe M, Williams MD, Cabanillas ME.
    Thyroid; 2018 Jan; 28(1):79-87. PubMed ID: 29161986
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma.
    Ito Y, Onoda N, Ito KI, Sugitani I, Takahashi S, Yamaguchi I, Kabu K, Tsukada K.
    Thyroid; 2017 Sep; 27(9):1142-1148. PubMed ID: 28635560
    [Abstract] [Full Text] [Related]

  • 11. Limited efficacy of lenvatinib in heavily pretreated anaplastic thyroid cancer: a French overview.
    Sparano C, Godbert Y, Attard M, Do Cao C, Zerdoud S, Roudaut N, Joly C, Berdelou A, Hadoux J, Lamartina L, Schlumberger M, Leboulleux S.
    Endocr Relat Cancer; 2021 Jan; 28(1):15-26. PubMed ID: 33112817
    [Abstract] [Full Text] [Related]

  • 12. Safety and Effectiveness of Lenvatinib in 594 Patients with Unresectable Thyroid Cancer in an All-Case Post-Marketing Observational Study in Japan.
    Takahashi S, Tahara M, Ito K, Tori M, Kiyota N, Yoshida K, Sakata Y, Yoshida A.
    Adv Ther; 2020 Sep; 37(9):3850-3862. PubMed ID: 32676927
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and Safety of Lenvatinib in Anaplastic Thyroid Carcinoma: A Meta-Analysis.
    Huang D, Zhang J, Zheng X, Gao M.
    Front Endocrinol (Lausanne); 2022 Sep; 13():920857. PubMed ID: 35846304
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Real-life use of lenvatinib in patients with differentiated thyroid cancer: experience from Argentina.
    Jerkovich F, Califano I, Bueno F, Carrera JM, Giglio R, Abelleira E, Pitoia F.
    Endocrine; 2020 Jul; 69(1):142-148. PubMed ID: 32253682
    [Abstract] [Full Text] [Related]

  • 18. Posterior Reversible Encephalopathy Syndrome after Lenvatinib Therapy in a Patient with Anaplastic Thyroid Carcinoma.
    Osawa Y, Gozawa R, Koyama K, Nakayama T, Sagoh T, Sunaga H.
    Intern Med; 2018 Apr 01; 57(7):1015-1019. PubMed ID: 29225265
    [Abstract] [Full Text] [Related]

  • 19. Neutrophil-to-Lymphocyte Ratio as a Prognostic Marker for Anaplastic Thyroid Cancer Treated With Lenvatinib.
    Fukuda N, Toda K, Fujiwara YU, Wang X, Ohmoto A, Urasaki T, Hayashi N, Sato Y, Nakano K, Yunokawa M, Ono M, Tomomatsu J, Mitani H, Takahashi S.
    In Vivo; 2020 Apr 01; 34(5):2859-2864. PubMed ID: 32871825
    [Abstract] [Full Text] [Related]

  • 20. Anti-PD-1/PD-L1 therapy augments lenvatinib's efficacy by favorably altering the immune microenvironment of murine anaplastic thyroid cancer.
    Gunda V, Gigliotti B, Ashry T, Ndishabandi D, McCarthy M, Zhou Z, Amin S, Lee KE, Stork T, Wirth L, Freeman GJ, Alessandrini A, Parangi S.
    Int J Cancer; 2019 May 01; 144(9):2266-2278. PubMed ID: 30515783
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.